Table 1.
Detailed summary of media compositions used for the differentiation of hPSCs into microglia-like cells
| hPSCs | Differentiation to Hematopoietic Progenitors | Differentiation to Microglia Precursors | Differentiation to Microglia-like Cells | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
Protocol 1 Muffat et al. |
Day − 1 – 0 DMEM/F12 + FBS (15%) +KOSR (5%) +FGF2 (4 ng/ml) |
Day 0–14 Neurobasal Medium + N2 (100x) + B27 (50x) + CSF1 (10 ng/ml) + IL-34 (10 ng/ml) |
Day 14–44 Neurobasal Medium + N2 (100x) + B27 (50x) + CSF1 (10 ng/ml) + IL-34 (10 ng/ml) |
Day 44–74 Neurobasal Medium + N2 (100x) + B27 (50x) + CSF1 (5 ng/ml) + IL-34 (100 ng/ml) |
|||||
|
Protocol 2 Pandya et al. |
Day − 2 – 0 mTeSR1 |
Day 0–4 STEMdiff APEL + VEGF (30 ng/ml) + BMP4 (30 ng/ml) + SCF (40 ng/ml) + Activin A (50 ng/ml) |
Day 4–15 STEMdiff APEL + BMP4 (25 ng/ml) + SCF (300 ng/ml) + IL-3 (10 ng/ml) + IL-6 (10 ng/ml) + Flt3L (300 ng/ml) + CSF3 (50 ng/ml) |
Day 15–29 (Astrocyte-MGL coculture) IMDM + FBS (10%) + IL-3 (20 ng/ml) + CSF1 (20 ng/ml) + CSF2 (20 ng/ml) |
|||||
|
Protocol 3 Abud et al. |
Day − 1 – 0 TeSR-E8 |
Day 0–2 IMDM/F12 (1:1) + ITSG-X (2%) + FGF2 (50 ng/ml) + BMP4 (50 ng/ml) + Activin A (12.5 ng/ml) + RhoKI (1 μM) + LiCl (2 mM) |
Day 2–4 IMDM/F12 (1:1) + ITSG-X (2%) + FGF2 (50 ng/ml) + VEGF (50 ng/ml) |
Day 4–10 IMDM/F12 (1:1) + ITSG-X (2%) + FGF2 (50 ng/ml) + VEGF (50 ng/ml) + TPO (50 ng/ml) + SCF (10 ng/ml) + IL-3 (10 ng/ml) + IL-6 (50 ng/ml) |
Day 10–14 DMEM/F12 (1:1) + ITSG (2%) + insulin (5 μg/ml) + N2 (0.5%l) + B27 (2%) + CSF1 (25 ng/ml) + IL-34 (100 ng/ml) + TGF-β (50 ng/ml) |
Day 14–35 DMEM/F12 (1:1) + ITSG (2%) + insulin (5 μg/ml) + N2 (0.5%l) + B27 (2%) + CSF1 (25 ng/ml) + IL-34 (100 ng/ml) + TGF-β (50 ng/ml) |
Day 35–38 DMEM/F12 (1:1) + ITSG (2%) + insulin (5 μg/ml) + N2 (0.5%l) + B27 (2%) + CSF1 (25 ng/ml) + IL-34 (100 ng/ml) + TGF-β (50 ng/ml) + CD200 (100 ng/ml) + CXCL1 (100 ng/ml) |
||
|
Protocol 4 Douvaras et al. |
Day − 3 – 0 mTeSR1 |
Day 0–4 mTeSR1 + BMP4 (80 ng/ml) |
Day 4–6 StemPro-34 SFM + FGF2 (25 ng/ml) + VEGF (80 ng/ml) + SCF (100 ng/ml) |
Day 6–14 StemPro-34 SFM + SCF (50 ng/ml) + TPO (5 ng/ml) + Flt3L (50 ng/ml) + IL-3 (50 ng/ml) + CSF1 (50 ng/ml) |
Day 14–25/50 StemPro-34 SFM + Flt3L (50 ng/ml) + CSF1 (50 ng/ml) + CSF2 (25 ng/ml) |
Day 25/50–45/65 RPMI-1640 + CSF2 (10 ng/ml) + IL-34 (100 ng/ml) |
|||
|
Protocol 5 Haenseler et al. |
Day − 2 – 0 mTeSR1 |
Day 0–4 mTeSR1 + VEGF (50 ng/ml) + BMP4 (50 ng/ml) + SCF (20 ng/ml) |
Day 4–14 X-VIVO15 + IL-3 (25 ng/ml) + CSF1 (100 ng/ml) |
Day 14–28/56 X-VIVO15 + IL-3 (25 ng/ml) + CSF1 (100 ng/ml) |
Day 28/56–42/70 Advanced DMEM/F12 + N2 (1%) + IL-34 (100 ng/ml) + CSF1 (10 ng/ml) |
||||
|
Protocol 6 Takata et al. |
Day − 1 – 0 mTeSR1 |
Day 0–2 StemPro-34 SFM + Transferrin (200 mg/ml) + BMP4 (5 ng/ml) + VEGF (50 ng/ml) + CHIR (2 μM) |
Day 2–4 StemPro-34 SFM + Transferrin (200 mg/ml) + BMP4 (5 ng/ml) + VEGF (50 ng/ml) + FGF2 (20 ng/ml) |
Day 4–6 StemPro-34 SFM + Transferrin (200 mg/ml) + VEGF (15 ng/ml) + FGF2 (5 ng/ml) |
Day 6–12 StemPro-34 SFM + Transferrin (200 mg/ml) + VEGF (10 ng/ml) + FGF2 (10 ng/ml) + SCF (50 ng/ml) + IL-3 (20 ng/ml) + IL-6 (10 ng/ml) + DKK1 (30 ng/ml) |
Day 12–16 StemPro-34 SFM + Transferrin (200 mg/ml) + FGF2 (10 ng/ml) + SCF (50 ng/ml) + IL-3 (20 ng/ml) + IL-6 (10 ng/ml) |
Day 16–25 IMDM/F12 (3:1) + N2 (1%) + B27 (2%) + CSF1 (50 ng/ml) |
Day 25–46 (Neuron-MGL coculture) not reported |
|